BR9714350A - Preparação e uso de ácidos orto-sulfonamido heteroaril hidroxâmicos com inibidores de metaloproteinases de matriz e da tace - Google Patents
Preparação e uso de ácidos orto-sulfonamido heteroaril hidroxâmicos com inibidores de metaloproteinases de matriz e da taceInfo
- Publication number
- BR9714350A BR9714350A BR9714350-2A BR9714350A BR9714350A BR 9714350 A BR9714350 A BR 9714350A BR 9714350 A BR9714350 A BR 9714350A BR 9714350 A BR9714350 A BR 9714350A
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- heteroaryl
- matrix
- tace
- hydroxamic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/42—Benzene-sulfonamido pyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D333/40—Thiophene-2-carboxylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Patente de Invenção: <B>"PREPARAçãO E USO DE áCIDOS ORTOSULFONAMIDO HETEROARIL HIDROXâMICOS COMO INIBIDORES DE METALOPROTEINASES DE MATRIZ E DA TACE"<D>. A presente invenção refere-se à descoberta de novos inibidores não-peptídicos e de baixo peso molecular de metaloproteinases de matriz (por exemplo, gelatinases, estromelisinas e colagenases) e da enzima de conversão de TNF-<244> (TACE, enzima de conversão do fator de necrose de tumor <244>), que são utilizáveis no tratamento de doenças em que essas enzimas estejam implicadas, como artrite, crescimento e metástase tumoral, angiogênese, ulceração tissular, cicatrização anormal de feridas, doença periodontal, doença óssea, proteinuria, doença de aneurisma da aorta, perda de cartilagem degenerativa após lesões articulares traumáticas, doenças desmielinizantes do sistema nervoso, rejeição de enxertos, caquexia, anorexia, inflamação, febre, resistência à insulina, choque séptico, insuficiência cardíaca congestiva, doença inflamatória do sistema nervoso central, doenças inflamatórias do intestino, infecção por HIV, degeneração macular relacionada à idade, retinopatia diabética, vitreorretinopatia proliferativa, retinopatia de prematuridade, inflamação ocular, ceratocone, síndrome de Sjogren, miopia, tumores oculares, angiogênese/neovascularização ocular. Os ácidos orto-sulfonamido aril hidroxâmicos inibidores de TACE e MMP da presente invenção são representados pela fórmula (1), em que a fração ácido hidroxâmico e a fração sulfonamido estão ligadas a carbonos adjacentes no grupo A, em que A é definido como uma heteroarila de 5 - 6 elementos com 1 a 3 heteroátomos independentemente selecionados dente N, O e S, e opcionalmente substituída com R^ 1^, R^ 2^ e R^ 3^; e Z, R^ 1^, R^ 2^, R^ 3^, R^ 4^, R^ 5^, R^ 6^, R^ 7^, R^ 8^ e R^ 9^ são descritos no relatório, e seus sais farmaceuticamente aceitáveis e seus isómeros óticos e diastereómeros.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73200996A | 1996-10-16 | 1996-10-16 | |
PCT/US1997/018519 WO1998016520A1 (en) | 1996-10-16 | 1997-10-08 | The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9714350A true BR9714350A (pt) | 2000-04-11 |
Family
ID=24941811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9714350-2A BR9714350A (pt) | 1996-10-16 | 1997-10-08 | Preparação e uso de ácidos orto-sulfonamido heteroaril hidroxâmicos com inibidores de metaloproteinases de matriz e da tace |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0934300B1 (pt) |
JP (1) | JP2001503037A (pt) |
KR (1) | KR20000049197A (pt) |
AR (1) | AR008677A1 (pt) |
AT (1) | ATE229949T1 (pt) |
AU (1) | AU743898B2 (pt) |
BR (1) | BR9714350A (pt) |
CA (1) | CA2268897A1 (pt) |
DE (1) | DE69718038D1 (pt) |
IL (1) | IL129148A0 (pt) |
NZ (1) | NZ335029A (pt) |
TW (1) | TW371657B (pt) |
WO (1) | WO1998016520A1 (pt) |
ZA (1) | ZA979238B (pt) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU743901B2 (en) * | 1996-10-16 | 2002-02-07 | Wyeth Holdings Corporation | Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloprote inase and tace inhibitors |
EP0967201A1 (en) * | 1998-05-20 | 1999-12-29 | Roche Diagnostics GmbH | Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
AR022424A1 (es) * | 1999-01-27 | 2002-09-04 | American Cyanamid Co | Compuestos derivados de acidos ortosulfonamido acetilenico e hidroxamico biciclico heteroarilo amido de acido fosfinico como inhibidores tace, composicionfarmaceutica que los comprende y el uso de los mismos para la manufactura de un medicamento |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
AR022422A1 (es) * | 1999-01-27 | 2002-09-04 | American Cyanamid Co | Inhibidores de tace acetilenicos de acido hidroxamico de heteroarilfulfonamida y amida del acido fosfinico |
US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6358980B1 (en) | 1999-01-27 | 2002-03-19 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US7141607B1 (en) | 2000-03-10 | 2006-11-28 | Insite Vision Incorporated | Methods and compositions for treating and inhibiting retinal neovascularization |
SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
MXPA04004010A (es) | 2001-11-01 | 2004-07-23 | Wyeth Corp | Acidos hidroxamicos de aril sulfonamida alenicos como inhibidores de tace y metaloproteinasa de matriz. |
PL370275A1 (en) * | 2001-11-22 | 2005-05-16 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
EA200400707A1 (ru) | 2001-11-22 | 2004-10-28 | Биовитрум Аб | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 |
US7074788B2 (en) | 2001-11-22 | 2006-07-11 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
US7491718B2 (en) | 2002-10-08 | 2009-02-17 | Abbott Laboratories | Sulfonamides having antiangiogenic and anticancer activity |
US20040157836A1 (en) * | 2002-10-08 | 2004-08-12 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
AU2003304456A1 (en) | 2002-12-23 | 2005-03-16 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
EP1449538A1 (en) * | 2003-02-21 | 2004-08-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation |
SE0301886D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use V |
SE0301884D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use III |
SE0301885D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use IV |
SE0301882D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use I |
SE0301883D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use II |
SE0301888D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use VII |
CA2630718A1 (en) | 2005-11-22 | 2007-05-31 | Amgen Inc. | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
KR20100033418A (ko) * | 2007-07-30 | 2010-03-29 | 엔싸이시브 파마슈티칼즈 인코퍼레이티드 | Ccr9 수용체의 조절제 및 그의 사용 방법 |
US8178699B2 (en) | 2008-07-30 | 2012-05-15 | Pfizer Inc. | Modulators of CCR9 receptor and methods of use thereof |
FR2947268B1 (fr) | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
FR2947270B1 (fr) | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
US20140275108A1 (en) | 2013-03-15 | 2014-09-18 | Galderma Research & Development | Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics |
IL237852A0 (en) | 2015-03-19 | 2016-03-24 | Yeda Res & Dev | Antibodies against amphigoline, medical preparations containing them and their use |
US20190008828A1 (en) | 2015-12-28 | 2019-01-10 | The U.S.A., As Represented By The Secretary Department Of Health And Human Services | Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells |
ES2695533T3 (es) | 2016-02-01 | 2019-01-08 | Galderma Res & Dev | Compuestos de bencenosulfonamida, método para su síntesis y uso de los mismos en medicina y cosméticos |
RU2748835C1 (ru) | 2017-11-27 | 2021-05-31 | Совет Научных И Прикладных Исследований | Индол(сульфонил)-n-гидроксибензамидные производные в качестве селективных ингибиторов hdac |
CA3115038A1 (en) | 2018-10-04 | 2020-04-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Egfr inhibitors for treating keratodermas |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
EP0821671B1 (en) * | 1995-04-20 | 2000-12-27 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors |
DE19542189A1 (de) * | 1995-11-13 | 1997-05-15 | Hoechst Ag | Cyclische N-substituierte alpha-Iminohydroxamsäuren |
JP2000502330A (ja) * | 1995-12-08 | 2000-02-29 | アグロン・ファーマシュウティカルズ・インコーポレーテッド | メタロプロテイナーゼ阻害薬、それらを含有する薬剤組成物および薬剤としてのそれらの使用、ならびにそれらの製造に有用な方法および中間体 |
AU743901B2 (en) * | 1996-10-16 | 2002-02-07 | Wyeth Holdings Corporation | Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloprote inase and tace inhibitors |
-
1997
- 1997-10-08 KR KR1019990703295A patent/KR20000049197A/ko not_active Application Discontinuation
- 1997-10-08 NZ NZ335029A patent/NZ335029A/xx unknown
- 1997-10-08 IL IL12914897A patent/IL129148A0/xx unknown
- 1997-10-08 JP JP10518522A patent/JP2001503037A/ja active Pending
- 1997-10-08 AU AU47560/97A patent/AU743898B2/en not_active Ceased
- 1997-10-08 CA CA002268897A patent/CA2268897A1/en not_active Abandoned
- 1997-10-08 DE DE69718038T patent/DE69718038D1/de not_active Expired - Lifetime
- 1997-10-08 AT AT97910099T patent/ATE229949T1/de not_active IP Right Cessation
- 1997-10-08 EP EP97910099A patent/EP0934300B1/en not_active Expired - Lifetime
- 1997-10-08 WO PCT/US1997/018519 patent/WO1998016520A1/en not_active Application Discontinuation
- 1997-10-08 BR BR9714350-2A patent/BR9714350A/pt not_active IP Right Cessation
- 1997-10-15 AR ARP970104750A patent/AR008677A1/es not_active Application Discontinuation
- 1997-10-15 ZA ZA9709238A patent/ZA979238B/xx unknown
- 1997-10-15 TW TW086114294A patent/TW371657B/zh active
Also Published As
Publication number | Publication date |
---|---|
AU4756097A (en) | 1998-05-11 |
DE69718038D1 (de) | 2003-01-30 |
AU743898B2 (en) | 2002-02-07 |
TW371657B (en) | 1999-10-11 |
ATE229949T1 (de) | 2003-01-15 |
CA2268897A1 (en) | 1998-04-23 |
WO1998016520A1 (en) | 1998-04-23 |
JP2001503037A (ja) | 2001-03-06 |
IL129148A0 (en) | 2000-02-17 |
ZA979238B (en) | 1999-07-15 |
EP0934300A1 (en) | 1999-08-11 |
KR20000049197A (ko) | 2000-07-25 |
NZ335029A (en) | 2000-10-27 |
AR008677A1 (es) | 2000-02-09 |
EP0934300B1 (en) | 2002-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9714350A (pt) | Preparação e uso de ácidos orto-sulfonamido heteroaril hidroxâmicos com inibidores de metaloproteinases de matriz e da tace | |
BR9712525A (pt) | O preparo e uso de ácidos orto-sulfonamido aril hidroxmicos como inibidores da metaloproteinase matricial e da tace | |
AR009990A1 (es) | Acidos orto-sulfonamido heteroaril hidroxamicos biciclicos como inhibidores de la metaloproteinasa de matriz y tace, uso de dichos compuestos para prepararmedicamentos, y composiciones farmaceuticas que los contienen | |
BR9712524A (pt) | Acidos beta-sulfonamido-hidroxmicos como inibidores de tace e de metaloproteinase de matriz | |
ES2934810T3 (es) | Moléculas químicas que inhiben el mecanismo de empalme para tratar enfermedades causadas por anomalías de empalme | |
RU2324684C2 (ru) | Пиримидиновые производные | |
SU1072803A3 (ru) | Способ получени производных фталазин-4-илуксусной кислоты или их солей | |
JP4507027B2 (ja) | Mmp阻害剤 | |
JP2013501008A (ja) | 抗ウイルス性化合物ならびにそれを含む医薬組成物 | |
ATE309194T1 (de) | Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften | |
HUP9902092A2 (hu) | Metalloproteináz gátló benzolszulfonamidszármazékok, intermedierjeik, előállításuk és alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények | |
BR0314577A (pt) | Derivados de triazol como inibidores do fator de crescimento de transformação (tgf) | |
AU2011302295B2 (en) | Inhibitors of viral entry into mammalian cells | |
CN101367749A (zh) | 一组胺基苯酰衍生物及其制备方法和应用 | |
MA28339A1 (fr) | Derives de l'acide 7- amino-4-quinolone-3-carboxylique substitues de maniere heterocyclique, methode pour leur production et leur utilisation en tant que medicaments | |
TW200306313A (en) | Phosphatase inhibitors | |
MA28340A1 (fr) | Derives de l'acide 7- amino-4- quinolone-3-carboxylique substitues par un groupe cycloalkyle, methode pour leur production et leur utilisation en tant que medicaments | |
ES2090081T3 (es) | Derivados de indolocarbazol, procedimientos para su obtencion y su empleo. | |
JP6929866B2 (ja) | 2,3−エポキシスクシニル誘導体、その調製方法及び使用 | |
CA3210278A1 (en) | Compositions and methods for viral sensitization | |
JPH1081666A (ja) | フタルイミド誘導体又はその塩、それらの製造方法及びそれらを含有する医薬組成物 | |
DK171487D0 (da) | Spergualinderivater, fremgangsmaade til deres fremstilling og deres anvendelse som laegemidler | |
CN109384694B (zh) | Sirt6小分子激动剂及其应用 | |
EA200500133A1 (ru) | Производные пирролидина в качестве антагонистов окситоцина | |
JP2004520349A (ja) | マトリックスメタロプロテイナーゼ(mmp)インヒビターとしての1−ジメルカプトアルキルキナゾリン−2,4(1h,3h)ジオン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1836 DE 14/03/2006. |